MDK83190
目录号 : KM18176 CAS No. : 79183-19-0 纯度 : 98%

MDK83190 是一种有效的细胞凋亡 (apoptosis) 激活剂,诱导 Apaf-1 寡聚化,以 cyto-c 依赖性方式增加 procaspase-9 加工和 caspase-3 活化。

规格 价格 是否有货 数量
10mg
In-stock
50mg
In-stock
100mg
In-stock
200mg 询价 In-stock
500mg 询价 In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

MDK83190 is a potent apoptosis activator, induces Apaf-1 oligomerization, increases procaspase-9 processing and subsequent caspase-3 activation in a cyto c-dependent Manner.

体外研究

MDK83190 (Compound 2) (1-50 μM; 2 hours) effects against cell lines of lymphoid origin (CCRF-CEM, MOLT-4, and Jurkat) with IC50 values ranging from 4 to 9 μM.
MDK83190 (Compound 2) (20 μM; 30 mins) activates procaspase-9 and procaspase-3 in a cyto c-dependent manner.
MDK83190 (Compound 2) (0.1-100 μM; 22 hours) strongly induces caspase-3 activation, PARP cleavage, and DNA fragmentation, and finally killing cells with an IC50 of 4 μM.

Cell Viability Assay

Cell Line: Leukemia cell line: CCRF-CEM cells, MOLT-4 cells, and Jurkat cells
Concentration: 1-50 μM
Incubation Time: 2 hours
Result: Was sensitive to compound 2-induced apoptosis.

Western Blot Analysis

Cell Line: Hela cells
Concentration: 20 μM
Incubation Time: 30 mins
Result: Induced procaspase-9 and procaspase-3 to active forms.

Apoptosis Analysis

Cell Line: Jurkat cells
Concentration: 0.1-100 μM
Incubation Time: 22 hours
Result: Resulted in apoptosis and finally killed cells.
分子式
C15H9Cl2NO2
分子量
306.14
CAS号
79183-19-0
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 46 mg/mL (150.26 mM)

* "≥" means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.2665 mL 16.3324 mL 32.6648 mL
5 mM 0.6533 mL 3.2665 mL 6.5330 mL
10 mM 0.3266 mL 1.6332 mL 3.2665 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (8.17 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.17 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

暂无相关参考文献
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2